Engflag

Sebclair

Quick links to important sections

Sebclair

Sebclair_ES

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sebclair

Property Description
Key Functional Agents Piroctone Olamine, Alglycera (Allantoin Glycyrrhetinic Acid), Telmesteine
Primary Form Cream (Oil-in-water emulsion)
Pharmacological Class Multimodal Topical Preparation (Anti-inflammatory, Antifungal, Keratolytic)
Route of Administration Topical (Dermatological)
Origin Derived Combination Product (Synthetic and Natural Extracts)

What Type of Topical Preparation is Sebclair?

Sebclair is specifically classified as a non-steroidal topical medical device, designed for dermatological application as a multimodal combination product. Its functional profile places it in the pharmacological class of preparations with combined anti-inflammatory, antifungal, and keratolytic properties. This product’s key differentiating factor is its non-steroidal mechanism, which is recognized for managing symptoms without the potential for negative effects typically associated with long-term topical corticosteroid use. Sebclair is primarily offered as an oil-in-water emulsion cream, ensuring the formula not only delivers active agents but also supports skin hydration and barrier function.

Key Functional Ingredients and Origin

The composition of Sebclair utilizes a blend of both synthetic and naturally derived functional ingredients to achieve its comprehensive effect. The formula features Piroctone Olamine, a key antimycotic agent that targets the organism often implicated in skin flaking and irritation by inhibiting fungal metabolism. It also contains Alglycera, a complex of Allantoin and Glycyrrhetinic Acid that provides a non-steroidal, steroid-like anti-inflammatory action. The inclusion of emollients and antioxidants like Shea Butter and Telmesteine highlights the product's focus on barrier enhancement, a crucial feature for skin compromised by chronic inflammation.

What is the General Purpose of Sebclair?

The general purpose of Sebclair is to provide combined, comprehensive relief from the core symptoms of skin discomfort by addressing the underlying factors of inflammation and yeast overgrowth. This type of preparation is used for managing moderate scaling and inflammation on areas like facial skin. The formulation achieves this by exerting an integrated anti-inflammatory, antifungal, and keratolytic action on the affected area, resulting in the general relief of symptoms such as intense itching (pruritus), redness (erythema), and associated scaling.

What side effects are possible with Sebclair?

The general principles governing the safety profile of Sebclair, a non-steroidal topical medical device containing Piroctone Olamine and Glycyrrhetinic Acid, are derived from regulatory documents detailing the characteristics of its active ingredients.

Adverse Reaction Scope

Adverse Reaction Categories Details from Regulatory Sources
Key Side Effect Categories Primarily localized dermatological reactions at the site of application.
Frequency Classification Most common effects are localized reactions; rare events include hypersensitivity.
System-Organ Classes Effects are concentrated in Skin and Subcutaneous Tissue Disorders. Eye Disorders are noted concerning accidental exposure.
Serious Adverse Reactions None are explicitly documented in official topical regulatory labeling for the product or its key components at typical concentrations.

Safety Classifications (High-Level)

Safety Element Regulatory Statement
Population-Specific Note Use in children under 2 years should be avoided unless professional direction is received, as documented in the labeling of Piroctone Olamine–containing products.
Dose/Exposure Patterns No specific time- or duration-related patterns are formally classified in regulatory documents.
Safety Restrictions For external use only. Contact with eyes or mucous membranes must be avoided.

The official safety information structures the understanding of risks by categorizing them as primarily localized and dermatological, which is consistent with the product's topical route of administration. Regulatory notes define constraints on use in young children and specify general safety precautions for external application. The overall profile focuses on managing the potential for localized irritation and allergic response.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory guidance concerning this topical preparation addresses situations of accidental exposure, as systemic toxicity from intended dermal use is considered low. Government safety documentation does not specify complex systemic manifestations associated with over-application to the skin; localized irritation or redness may occur but does not represent a systemic overdose.

The primary circumstance that requires an emergency response is accidental oral ingestion. Due to the ingredients and low expected systemic absorption, specific severe or life-threatening systemic outcomes are not explicitly detailed in regulatory documentation for this product class. Nevertheless, in the event the cream is swallowed, government health authorities mandate specific emergency action: it is required to seek immediate medical attention or contact a Poison Control Center right away. This requirement is non-negotiable and constitutes the core of the official overdose management plan.

Management, as described in official documents, is strictly restricted to symptomatic and supportive treatment, a standard measure applied when no specific antidote is known to be available. Overdose guidance also includes the standing mandate to keep the product out of reach of children to prevent this primary risk of accidental oral exposure, which is the sole focus of the official regulatory profile.

Therapeutic Uses of Sebclair

What Sebclair Treats: Main Uses and Benefits

Sebclair may be used as part of supportive therapy generally used in situations involving certain distressing symptoms associated with seborrheic dermatitis. Primary goals of therapy for this condition are to clear visible signs and reduce bothersome symptoms like pruritus. The product is applied in scenarios where additional management of discomfort is required, and it may assist in addressing symptom clusters that include itching, scaling, and reddening (erythema).

Symptom Relief and Stabilization

This section addresses symptoms related to physical discomfort in conditions characterized by periods of heightened symptoms. Sebclair is relevant for easing discomfort by supporting the normal skin barrier function, and may help with reducing the appearance of flaking and skin reddening. It contributes to improved day-to-day comfort and helps ease the overall symptom load during periods of heightened symptoms.

Quick Fact: Relief for Itching
Sebclair is commonly used to help with symptoms related to physical discomfort, such as pruritus (itching), during symptomatic periods.

Therapeutic Domains

The product is applied across domains where short-term symptom management is appropriate. Sebclair is considered relevant for addressing manifestations associated with seborrheic dermatitis, including symptoms related to physical discomfort, scaling, and localized discomfort.

Eligibility and Restrictions for Use

Sebclair is regulated as a topical medical device, and its official eligibility profile is defined by local safety considerations rather than systemic restrictions.

The absolute restriction for Sebclair is contraindication in patients with a documented hypersensitivity or allergy to any of the product's components, including its active ingredients or excipients such as Shea Butter. Individuals with a known allergy to any ingredient must not use the product.

In terms of age, the official regulatory profile supports use across a broad range of life stages. It is established for use in adults and is also specifically documented for use in infants for the management of symptoms associated with cradle cap. The product does not carry an explicit minimum age restriction.

For physiological status, use during pregnancy and lactation is generally permitted, but the official regulatory information advises consulting a physician or pharmacist prior to application. This designation identifies this group as a conditional use population. Due to the product's topical, non-systemic application, there are no documented label restrictions related to hepatic or renal impairment. The primary eligibility criterion is the absence of local component allergies.

What should I know about interactions with other medicines?

The official regulatory profile for Sebclair, a non-steroidal topical preparation, is defined by the absence of documented systemic drug-drug interactions. As the product is intended for localized application and results in negligible systemic exposure to its functional agents, government regulatory documentation (such as prescribing information from the EMA or FDA) does not typically include formal warnings for pharmacokinetic or pharmacodynamic interactions with co-administered systemic medicines. The regulatory-aligned high-level statement regarding co-administration is structured as follows:

Interaction Domain Regulatory Statement
Systemic Interactions None formally documented; the localized application results in negligible systemic effects.
Contraindicated Combinations No substances are explicitly prohibited for co-administration in regulatory documentation.
Metabolic or Transporter Effects No formal interactions involving CYP enzymes, P-gp, or other drug transporters are documented.
Food, Alcohol, or Herbal Products No specific interactions or restrictions are formally cited in official labeling.
Timing Separation Rules No mandatory timing separation rules between applications are cited in official regulatory documents.

This interaction structure confirms that no formal prohibitions or specific dose-adjustment warnings related to systemic drug interactions are required in the official labeling. The interaction profile reflects the limited risk of systemic exposure inherent to the topical route of administration, which differentiates it from orally administered medicinal products.

Mechanism of Action

Sebclair's action involves a multi-target approach within the stratum corneum and underlying dermal layers. The formulation's components selectively accumulate at the epidermal-dermal junction and within the sebaceous glands. Certain active agents function as non-competitive inhibitors of 5-lipoxygenase (5-LO), modifying the metabolic pathway of arachidonic acid. This inhibition reduces the intracellular concentration and subsequent release of pro-inflammatory leukotrienes. Simultaneously, other constituents exert antifungal activity against the lipophilic yeast Malassezia by disrupting its cell membrane integrity and inhibiting ergosterol synthesis. This interaction leads to a reduction in the colonization density of the organism on the skin surface. Further mechanistic effects include a physical modulation of the skin barrier function, enhancing the hydrophobic nature of the stratum corneum and altering trans-epidermal water loss. The overall cascade involves diminished pro-inflammatory mediator production, decreased fungal proliferation, and structural stabilization of the epidermal layer, resulting in systemic physiological modulation of skin surface microflora and local immune cell signaling.

Dosage and Administration Information

How to Use Sebclair

This section outlines the general administration patterns for Sebclair Cream, based on the established usage protocols for a non-systemic topical preparation.

Administration Protocol

Feature Guideline
Route of Administration The product is restricted to topical (dermatological) application for external use only.
Dosing Regimen The standard regimen involves applying a thin layer to the affected surface areas of the skin, as numerical volumetric doses are not specified.
Special Procedural Conditions The cream must be gently massaged into the skin until it is fully absorbed. Administration requires avoiding contact with the eyes.

Frequency and Duration

Administration frequency for Sebclair is structured to address the usage context:

  • Acute Course: Application is typically specified as twice daily (two times per day) during the initial period of symptoms.
  • Maintenance: Use may transition to a once-daily or as-needed basis for long-term supportive management to help prevent recurrence.

While the product is often applied over an initial course of approximately four weeks, the non-steroidal nature permits use for ongoing management. Specific dose adjustments for systemic conditions, such as renal or hepatic impairment, are neither required nor specified due to the external route of administration. These labeled instructions define the standardized approach to using the medicine.

Recent Clinical Evidence

Evidence for Use in Seborrheic Dermatitis of the Face

Research examined the product in adult individuals with mild to moderate Seborrheic Dermatitis (SD) that affects the face. The primary research consists of short-term, randomized controlled trials (RCTs). These studies monitored key outcomes related to SD, including standardized clinical tools like the Investigator Global Assessment (IGA) and patient-reported outcomes describing perceived discomfort, such as pruritus (itching). Researchers also examined specific symptom features like erythema (redness) and scaling (flaking).

Comparison to Standard and Vehicle Treatments

Some short-term RCTs were conducted to directly compare the investigational formulation against an inactive control (vehicle) cream. Other research scenarios involved comparing Sebclair alongside a commonly used short-term treatment, such as a topical corticosteroid. Studies reported patterns in clinical severity scores (IGA and SASI-F) when Sebclair was examined alongside the comparators, and research describes how patients reported their experience across the different study groups.

Limitations and Research Gaps

The available evidence is mainly derived from studies involving adult subjects with mild to moderate symptoms, meaning the results apply only to the populations studied. Limited information is available regarding studies in severe cases of seborrheic dermatitis.

Furthermore, the primary evaluation period in most clinical trials was short-term, typically four weeks. Because the follow-up durations were constrained, research regarding long-term outcomes is not fully established. The sample sizes were modest in the published clinical trials, and the evidence is limited regarding the product's role in the long-term management of conditions involving periods of heightened symptoms.

Key Studies & References Efficacy of SEBCLAIR® Cream for Moderate Seborrhoeic Dermatitis on The Face as An Adjuvant Therapy (Randomised Clinical Trial, Double Blind).

Frequently Asked Questions (FAQ)

Common questions about Sebclair (FAQ)

Q: Is Sebclair classified as a medical device, a drug, or a cosmetic product in official documents?

According to official regulatory documents, Sebclair is classified as a non-steroidal topical medical device. This classification means the product is intended for dermatological application to manage skin symptoms, rather than being a systemic drug.

Q: What is the main difference between Sebclair cream and Sebclair shampoo?

Official product information confirms that Sebclair is available in a range of formulations, including a cream and a shampoo. These different forms are intended to manage symptoms of seborrheic dermatitis on various affected areas, such as the skin of the face or the scalp.

Q: What are the key active ingredients in Sebclair and what is their stated purpose?

The product utilizes several key functional ingredients. Piroctone Olamine is included for its antimycotic (anti-fungal) properties. Other components, such as Glycyrrhetinic Acid and Telmesteine, contribute antioxidant and anti-inflammatory properties, all aiming to manage the underlying factors of the condition.

Q: Is it common to feel a mild warming or slight burning sensation when first applying Sebclair?

Clinical data indicates that patient experience of localized sensations, including burning or stinging, was monitored as a possible localized sensation during product trials. Experiencing a brief, mild warming or stinging upon initial application is therefore an occurrence that was tracked in studies.

Q: What types of temporary local skin reactions have been reported during studies of Sebclair?

The clinical studies tracked localized dermatological reactions. The most common monitored effects included patient-assessed pruritus (itching) and investigator-assessed erythema (redness) and scaling. These reactions are typically temporary and localized to the application site.

Q: Does Sebclair cause the skin to thin or change color with prolonged use?

Official information describes Sebclair as a non-steroidal treatment. Because it does not contain corticosteroids, it is not generally associated with effects like skin thinning, which are commonly linked to prolonged use of topical steroid products.

Q: Is there a known 'rebound' phenomenon associated with stopping the use of Sebclair?

Official product information confirms that, as a non-steroidal product line, Sebclair does not cause the 'rebound effect' often seen when stopping the use of topical corticosteroids.

Q: Can Sebclair be used on sensitive facial skin?

Research studies for the product were conducted on the face. Product labeling and descriptions indicate that the formula is suitable for use on the face and is specifically described as being appropriate for sensitive and irritated skin.

Q: What is the guidance regarding the use of Sebclair in infants for cradle cap?

Official guidance confirms use in infants for cradle cap management, and specific application instructions are detailed in the product's official labeling. This allows for application to the affected area as needed, based on established protocols.

Q: Are there any ingredients in Sebclair that people with certain allergies should be aware of?

Official warnings state that people with a known history of hypersensitivity or allergy to any of the components must consult a healthcare professional. Individuals should review the full product composition list, which includes components such as Shea Butter, for known allergens before application.

Q: Does Sebclair leave a greasy or noticeable residue after it has been absorbed?

Product descriptions frequently state that the cream formulation is non-greasy. It is designed to feel light on the skin and is described as leaving a smooth, velvety matte finish after it has been fully absorbed.

Q: How long does it usually take before users report noticing an effect from Sebclair?

Clinical trials tracked the product's efficacy over a 28-day period. Reports from clinical trials noted that initial reductions in key symptoms, such as redness, were observed in some individuals as early as Day 7.

Q: What are the signs that Sebclair might be starting to work?

The product is designed to relieve the core symptoms of the condition. The signs that it is beginning to work include a reduction in patient-assessed itching (pruritus) and a noticeable decrease in investigator-assessed scaling and redness (erythema).

Q: Is Sebclair supported by clinical studies?

Yes, official product information confirms that Sebclair is supported by clinical data. The evidence includes randomized, double-blind, controlled trials that examined the product's efficacy and safety profile in the target population.

Q: What does the research say about Sebclair compared to a vehicle (placebo) cream?

Research studies, including short-term controlled trials, compared Sebclair to an inactive vehicle cream. These clinical trials observed that Sebclair demonstrated a significantly higher rate of improvement in clinical severity scores compared to the vehicle cream alone.

Q: Why is Sebclair available in different forms (cream, shampoo, lotion)?

The availability of different forms, such as a cream and a shampoo, is intended to allow for the management of seborrheic dermatitis across the various areas it affects. These areas commonly include the face, body, and the scalp.

Q: Does Sebclair contain alcohol or parabens that might irritate sensitive skin?

Official product descriptions often confirm that the cream formulation does not contain parabens. Information regarding other potential irritants is found within the full product composition list.

Q: Why do official documents mention avoiding use with products containing Resorcinol?

Official product information lists Resorcinol as a substance that Sebclair may interact with. Official information indicates that users should seek guidance from a healthcare professional if considering using Sebclair concurrently with products containing Resorcinol.

Q: What is the difference between an allergic reaction and a known side effect of Sebclair?

Official safety information distinguishes between reported localized adverse events (side effects), such as temporary redness, and the explicit warning for people with a known history of hypersensitivity or allergy. Hypersensitivity reactions are considered a more serious category of adverse events.

How should Sebclair be stored and disposed of?

How to Store and Dispose of Sebclair?

The storage and handling of Sebclair Cream must adhere to conditions specified in regulatory labeling to maintain the product's quality and ensure safety.

Official Storage Requirements

The product must be stored at a temperature at or below 25 C (77 F) and away from direct heat to prevent stability issues. Regulatory requirements mandate that the product must not be used if the container is opened or damaged.

Child Safety and Disposal

For safety, Sebclair is required to be kept out of the reach of children. Official documentation advises that disposal of any unused or expired cream should be carried out in accordance with local regulatory and waste-management guidelines, as specific instructions for household disposal are typically not provided.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Sebclair found in:

A-Z Index: